Abcellera Biologics Inc ABCL

$12.18 +1.06 (9.53%)

Valuation

Market cap
3,762,117,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
2,467,939
Avg volume
4,729,820
Day's range
$11.31 – $12.33
Shares out
306,611,000
Stochastic %K
2%
Beta
1.41
Analysts
Strong Buy
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Stocktradesmoon Nov 3, 8:48 PM
$ABCL $REGN $MRNA $PFE $SLS $ABCL I’m sure that Carl and other team members of management are market buying today!!! Mark this post!! News After Hours today ahead of 3 Catalyst Events in a few days Starting WITH Earnings November 9!! I’ve seen this happen before and we get NEWS 🗞️ after hours that takes us to $15.00+
0 replies
Stocktradesmoon Nov 3, 8:38 PM
$ABCL $MRNA $REGN $SLS $PFE $ABCL 👀🔥 ABcellera 🔥!!! There is zero fundamental reason to support ABCL falling in price. If anything, the stock is too cheap right now. People don’t understand the sheer magnitude of what this company will do, and sadly those people will be left behind… I’m just sitting back with a boatload of shares waiting for the actual breakout to happen. We’ve seen nothing yet, IMO! Don’t get me wrong, I welcome sales in the market and will just keep buying but I don’t think we go anywhere but up…
0 replies
Stocktradesmoon Nov 3, 8:32 PM
$ABCL $PFE $MRNA $REGN $SLS
0 replies
erpy Nov 3, 8:15 PM
$ABCL its not if for me!!! Its simply when???
0 replies
Stocktradesmoon Nov 3, 8:13 PM
$ABCL $MRNA $REGN $SLS $PFE $ABCL 🧬 13 Dollar Resistance 13 dollars is in sight. But this guy won’t open the door without a fight. 😂 Now what we need isn’t the chart—it’s a reason to break through. 🔥November 9: Q3 earnings and pipeline update. November 11: Stifel Healthcare Conference. November 16: Jefferies Global Healthcare Conference in London. The market’s already seen the Phase 2 topline. This time, it needs to show something more in 12-week durability, sleep, safety, and redosing. The chart brought us right to the door at 13 dollars. The one to kick it down is the data. Alright, 635. Let’s OPEN that door. 🚪💥
0 replies
Stocktradesmoon Nov 3, 7:43 PM
$ABCL $REGN $PFE $SYRE $SLS $ABCL : 4 new Street initiations in 5 weeks 👀 Do people trade price targets? Goldman (Sep 24): Neutral, $13 JPMorgan (Sep 29): Overweight, $17 UBS (Oct 12): Buy, $18 Jefferies (Oct 30): Buy, $21 The big banks are showing up. On the chart I'm watching for a higher low to set up a 4th attempt at the $15 breakout. Fourth time's the charm. 👀😉
0 replies
DeMampCamp Nov 3, 7:37 PM
$ABCL 🤡 🤡 🤡 🤡
1 replies
SuperGreenToday Nov 3, 7:29 PM
$ABCL Share Price: $12.12 Contract Selected: Apr 16, 2027 $10 Calls Buy Zone: $2.89 – $3.57 Target Zone: $4.86 – $5.94 Potential Upside: 59% ROI Time to Expiration: 163 Days | Updates via https://fxcapta.com/stockinfo/
0 replies